findmyKOL
Clinical trialNCT00220740CompletedPhase 3Interventional

Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

SponsorGrifols Therapeutics LLCEnrollment117Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The intent of this study is to demonstrate the efficacy and safety of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in newly or previously diagnosed CIDP subjects. Eight courses of treatment with either placebo or IGIV-C will occur every 3 weeks. Neurological function will be measured by Inflammatory Neuropathy Cause and Treatment (INCAT) scores. Patients who deteriorate or show no improvement between day 16 and month 6 will receive the alternate study drug for an additional 6 months.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

32 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina
  • Fundacion Para la Lucha Contra Las Enfermedades Neurologicas de la Infacia (fleni)

    Buenos Aires, Argentina

  • Hospital Frances

    Buenos Aires, Argentina

  • Hospital Ramos Mejia

    Buenos Aires, Argentina

  • Instituto de Neurociencias Buenos Aires (ineba)

    Capital Federal, Argentina

Canada
  • Vancouver Hospital and Health Sciences Center

    Vancouver, British Columbia, Canada

Czechia
  • Fakultní Nemocnice Brno

    Brno, Czechia

  • Fakultní Nemocnice Ostrava

    Ostrava-Poruba, Czechia

  • Neurologická Klinika Pardubice

    Pardubice, Czechia

  • Fakultní Nemocnice Motol

    Prague, Czechia

Germany
  • Jüdisches Krankenhaus

    Berlin, Germany

Israel
  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • Chaim Sheba Medical Center

    Tel Litwinsky, Israel

  • Assaf Harofe Medical Center

    Zrifin, Israel

Italy
  • Dipartimento Di Neuroscienze, Sezione Di Neurologia, Ao Chieti

    Chieti, Italy

  • Univesita Delgi Studi Di Genova, Dipartimento Di Scienze, Neurologiche E Della Visione

    Genova, Italy

  • Hospital San Raffaele

    Milan, Italy

Mexico
  • Antiguo Hospital Civil de Guadalajara

    Guadalajara, Jalisco, Mexico

  • Hospital Angel Leano, Neurology Department

    Guadalajara, Jalisco, Mexico

  • Hospital Central San Luis Potosi, Neurology Department

    San Luis Potosí City, Mexico

Poland
  • Centre of Clinical Neurology, Neurology Department

    Cracow, Poland

  • County Specialist Hospital, Neurology Department

    Gdansk, Poland

  • Barlicki Hospital

    Lodz, Poland

  • Medical Acedemy, Clinical Hospital, Neurology Department

    Lubin, Poland

  • Central Clinical Hospital, Medical Academy Warsaw

    Warsaw, Poland

  • County Hospital

    Zgierz, Poland

Serbia
  • University Hospital, University of Belgrade

    Belgrade, Serbia

United States
  • Yale University School of Medicine

    New Haven, Connecticut, United States

  • Saint Louis University Medical Center

    St Louis, Missouri, United States

  • Columbia University

    New York, New York, United States

  • Wake Forest University-School of Medicine

    Winston-Salem, North Carolina, United States

  • Cleveland Clinic

    Cleveland, Ohio, United States

  • University of Texas-Southwestern Medical Center at Dallas

    Dallas, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Albumin 25%, United States PharmacopeiaGLOBULIN,IMMUNE
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Apr 2004
Primary completion
30 Jun 2006
Completion
30 Jun 2006
Last update posted
23 Mar 2016
Registered enrollment
117
Registry id
NCT00220740
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.